Orange Book product · Generic (ANDA)
VASOPRESSIN
VASOPRESSIN
At a glance
Aug 05, 2022
Approved
Generic (ANDA)
Application
AP
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Aug 05, 2022
3 yr 11 mo ago
Today
Pharmaceutical detail
Active ingredient
VASOPRESSIN
Strength
20UNITS/ML (20UNITS/ML)
Dosage form
SOLUTION
Route
INTRAVENOUS
TE code
AP
Application
ANDA 212944
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of VASOPRESSIN
- 2024VASOPRESSIN IN SODIUM CHLORIDE 0.9%Brand (NDA)
NDA 217766 · LONG GROVE PHARMS
- 2023VASOPRESSIN IN SODIUM CHLORIDE 0.9%Brand (NDA)
NDA 217569 · BAXTER HLTHCARE CORP
- 2020VASOPRESSINBrand (NDA)
NDA 212593 · AM REGENT
- 2014VASOSTRICTBrand (NDA)
NDA 204485 · PH HEALTH
- 2026VASOPRESSINGeneric (ANDA)
ANDA 212068 · SANDOZ
- 2026VASOPRESSINGeneric (ANDA)
ANDA 212069 · SANDOZ
- 2024VASOPRESSINGeneric (ANDA)
ANDA 213988 · DR REDDYS
- 2024VASOPRESSINGeneric (ANDA)
ANDA 216963 · GLAND
- 2023VASOPRESSINGeneric (ANDA)
ANDA 217987 · CIPLA
- 2023VASOPRESSINGeneric (ANDA)
ANDA 213206 · FRESENIUS KABI USA
- 2022VASOPRESSINGeneric (ANDA)
ANDA 214314 · EUGIA PHARMA
- 2022VASOPRESSINGeneric (ANDA)
ANDA 211857 · AMPHASTAR PHARMS INC
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
